Accelerated discovery of thermostable mRNA-lipid nanoparticle vaccines using data-efficient AI

Key Points:

• mRNA vaccines such as Moderna's mRNA-1273 and Pfizer-BioNTech's BNT162b2 have demonstrated high efficacy and safety profiles in preventing COVID-19, as reported in major clinical trials (Baden et al., 2021; Polack et al., 2020).
• Stability and storage remain critical challenges for mRNA vaccines, with ongoing research exploring lyophilization, lipid nanoparticle formulation, and novel drying technologies to improve thermostability and extend shelf life (Muramatsu et al., 2022; Ai et al., 2023; Crommelin et al., 2021).
• Innovations in delivery methods, including microneedle patches and selective organ targeting nanoparticles, are advancing to enhance vaccine administration, reduce pain, and enable precise tissue-specific mRNA delivery (vander Straeten et al., 2024; Sakers et al., 2025; Cheng et al., 2020).
• Artificial intelligence and data-driven approaches are increasingly employed to optimize vaccine formulation, stability, and manufacturing processes, accelerating discovery and improving efficiency in mRNA vaccine development (Zhang et al., 2025; Tian et al., 2023; Wahl et al., 2024).
• Addressing vaccine inequity and the cold chain's economic and environmental impacts remain global priorities, highlighting the need for thermostable vaccines and improved distribution strategies to ensure broader access (Ferranna, 2024; Lutzmayer et al., 2025).